Safety and Efficacy of Ustekinumab in the Treatment of Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis.
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2013
At a glance
- Drugs Ustekinumab (Primary)
- Indications Palmoplantar pustulosis
- Focus Registrational; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Aug 2012 Actual patient number amended from 40 to 433 as reported by ClinicalTrials.gov record.
- 06 Aug 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov record.